<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00439374</url>
  </required_header>
  <id_info>
    <org_study_id>HD36801 SCAN</org_study_id>
    <secondary_id>U10HD021410</secondary_id>
    <secondary_id>U10HD027869</secondary_id>
    <secondary_id>U10HD027917</secondary_id>
    <secondary_id>U10HD053097</secondary_id>
    <secondary_id>U10HD027915</secondary_id>
    <secondary_id>U10HD034116</secondary_id>
    <secondary_id>U10HD034208</secondary_id>
    <secondary_id>U10HD034136</secondary_id>
    <secondary_id>U10HD040500</secondary_id>
    <secondary_id>U10HD040485</secondary_id>
    <secondary_id>U10HD040544</secondary_id>
    <secondary_id>U10HD040545</secondary_id>
    <secondary_id>U10HD040560</secondary_id>
    <secondary_id>U10HD040512</secondary_id>
    <secondary_id>U10HD036801</secondary_id>
    <secondary_id>U10HD053118</secondary_id>
    <nct_id>NCT00439374</nct_id>
  </id_info>
  <brief_title>RCT of Progesterone to Prevent Preterm Birth in Nulliparous Women With a Short Cervix</brief_title>
  <acronym>SCAN</acronym>
  <official_title>A Randomized Trial of 17 Alpha-Hydroxyprogesterone Caproate for Prevention of Preterm Birth in Nulliparous Women With a Short Cervix</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The George Washington University Biostatistics Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>The George Washington University Biostatistics Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to see if giving progesterone medication to pregnant women, who
      have never delivered a baby after 19 weeks of pregnancy and who have a short cervix, lowers
      the risk of early delivery and improves the health of their baby.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Preterm births, defined as the delivery of a baby less than 37 weeks of gestation, are
      responsible for the majority of neonatal mortality and morbidities. Studies have shown that a
      number of risk factors, including never having a baby before and having a short cervix are
      associated with early delivery. Recently the NICHD did a study in women who were pregnant
      again after having delivered preterm. It showed that giving 17 alpha-hydroxyprogesterone
      caproate (17P) medication during pregnancy decreased the chance of delivering another preterm
      baby by 34%. This placebo-controlled randomized clinical trial will address the primary
      research question: does treatment with 17P initiated before 23 weeks of gestation prevent
      delivery prior to 37 weeks in nulliparous women with a singleton gestation who have a short
      cervix?
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Halted by NICHD after recommendation by DSMC to stop for futility
  </why_stopped>
  <start_date>April 2007</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Treatment with 17 alpha-hydroxyprogesterone caproate via weekly injections of 250 mg of 17p until 37 weeks gestation or delivery vs. weekly injections of placebo oil until 37 weeks gestation or delivery.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
    <masking_description>Patients and care providers are masked to treatment assignment.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Delivering Before 37 Weeks Gestation</measure>
    <time_frame>Delivery before 37 weeks gestation</time_frame>
    <description>Number of participants delivering before 37 weeks gestation by indication</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Gestational Age at Delivery</measure>
    <time_frame>Delivery</time_frame>
    <description>Mean gestational age at delivery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Preterm Premature Rupture of Membranes</measure>
    <time_frame>&lt;37 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Delivered Before 35 Weeks Gestation</measure>
    <time_frame>Delivery</time_frame>
    <description>Delivery before 35 weeks gestation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Delivered Before 32 Weeks Gestation</measure>
    <time_frame>Delivery</time_frame>
    <description>Delivery before 32 weeks gestation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Delivered Before 28 Weeks Gestation</measure>
    <time_frame>Delivery</time_frame>
    <description>Delivery before 28 weeks gestation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Visited the Hospital Due to Preterm Labor</measure>
    <time_frame>Between randomization and 37 weeks gestation</time_frame>
    <description>Number of participants who visited the hospital due to preterm labor before 37 weeks gestation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Underwent Tocolytic Therapy</measure>
    <time_frame>Any time during pregnancy from randomization to delivery, a timeframe up to 20 weeks</time_frame>
    <description>Number of participants who underwent tocolytic therapy during pregnancy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Underwent Corticosteroid Therapy</measure>
    <time_frame>Any time during pregnancy from randomization to delivery, a timeframe up to 20 weeks</time_frame>
    <description>Number of participants who underwent corticosteroid therapy in pregnancy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Had a Cerclage Placement</measure>
    <time_frame>Any time during pregnancy from randomization to delivery, a timeframe up to 20 weeks</time_frame>
    <description>Number of participants who had a cerclage placement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experiencing Gestational Hypertension or Preeclampsia</measure>
    <time_frame>Any time during pregnancy from randomization to delivery, a timeframe up to 20 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Gestational Diabetes Mellitus</measure>
    <time_frame>Any time during pregnancy from randomization to delivery, a timeframe up to 20 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experiencing Cholestasis</measure>
    <time_frame>Any time during pregnancy from randomization to delivery, a timeframe up to 20 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Experienced Placental Abruption</measure>
    <time_frame>Any time during pregnancy from randomization to delivery, a timeframe up to 20 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Experienced Chorioamnionitis</measure>
    <time_frame>Any time during pregnancy from randomization to delivery, a timeframe up to 20 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Had Cesarean Delivery</measure>
    <time_frame>delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Reported Side Effects</measure>
    <time_frame>Any time during pregnancy from randomization to delivery, a timeframe up to 20 weeks</time_frame>
    <description>Number of participants who reported any side effect, nausea, urticaria, and/or an issue at the injection site</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Meeting the Composite Adverse Perinatal Outcome and Components</measure>
    <time_frame>within 72 hours of delivery</time_frame>
    <description>comprised of fetal or infant death, respiratory distress syndrome, intraventricular hemorrhage (grades 3 and 4), periventricular leukomalacia, necrotizing enterocolitis (stage II and III), Bronchopulmonary dysplasia /chronic lung disease, retinopathy of prematurity (stage III or higher), early onset sepsis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Birth Weight</measure>
    <time_frame>Delivery</time_frame>
    <description>Birth weight as measured in grams</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Birth Weight by Count of Participants</measure>
    <time_frame>Delivery</time_frame>
    <description>Birth weight by count of participants &lt; 2500 grams and &lt; 1500 grams</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Neonates Who Measured Small for Gestational Age</measure>
    <time_frame>Delivery</time_frame>
    <description>Birth weight percentile and small for gestational age &lt;10th percentile based on number of weeks and gender.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Apgar Score of Less Than 7 at 5 Minutes</measure>
    <time_frame>5 minutes post delivery</time_frame>
    <description>The Apgar score is a simple method of quickly assessing the health and vital signs of a newborn baby created by and named after Dr. Virginia Apgar. Apgar testing assesses Appearance, Pulse, Grimace and Activity in a newborn and is typically done at one and five minutes after a baby is born, and it may be repeated at 10, 15, and 20 minutes if the score is low. The five criteria are each scored as 0, 1, or 2 (two being the best), and the total score is calculated by then adding the five values obtained. Agar scores of 0-3 are critically low, 4-6 are below normal, and indicate that the baby likely requires medical intervention, scores of 7+ are considered normal. The lower the Apgar score, the more alert the medical team should be to the possibility of the baby requiring intervention. Some components of the Apgar score are subjective, and there are cases in which a baby requires urgent medical treatment despite having a high Apgar score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Neonates With a Major Congenital Anomaly</measure>
    <time_frame>Delivery</time_frame>
    <description>Presence of a major congenital anomaly at birth</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Neonates With Patent Ductus Arteriosus</measure>
    <time_frame>Delivery through neonatal discharge</time_frame>
    <description>Number of neonates diagnosed with the heart defect patent ductus arteriosus</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Neonates Experiencing Seizures</measure>
    <time_frame>Delivery through neonatal discharge</time_frame>
    <description>Number of neonates experiencing seizures from delivery to hospital discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Neonates Admitted to NICU</measure>
    <time_frame>Delivery through hospital discharge</time_frame>
    <description>Admission to the neonatal intensive care unit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Length of NICU Stay</measure>
    <time_frame>NICU admission through NICU discharge</time_frame>
    <description>Median length of stay in the neonatal intensive care unit in days</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">657</enrollment>
  <condition>Preterm Delivery</condition>
  <condition>Cervical Length</condition>
  <arm_group>
    <arm_group_label>17 alpha-hydroxyprogesterone caproate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>250 mg of 17 alpha-hydroxyprogesterone caproate given by weekly injection until 37 weeks gestation or delivery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo oil given by weekly injection until 37 weeks gestation or delivery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>17 alpha-hydroxyprogesterone caproate</intervention_name>
    <description>Coded study medication is sterile solution containing 250 mg/mL of 17 alpha-hydroxyprogesterone caproate in castor oil with benzyl benzoate and benzyl alcohol as a preservative; placebo is same without the active ingredient. Study drug is administered as weekly 1 ml intramuscular injections until 36 week 6 days of gestation or delivery, whichever occurs first.</description>
    <arm_group_label>17 alpha-hydroxyprogesterone caproate</arm_group_label>
    <other_name>17 AHP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo Oil</intervention_name>
    <description>Placebo oil is a 250 mg/mL solution of castor oil with benzyl benzoate and benzyl alcohol as a preservative</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Nulliparous

          -  Cervical length as measured on transvaginal examination &lt; 30mm between gestational
             ages of 16 weeks 0 days to 22 weeks 3 days

          -  Gestational age 16 weeks 3 days to 22 weeks 6 days at time of randomization

        Exclusion Criteria:

          -  Multifetal gestation

          -  Progesterone treatment after 14 weeks 6 days during current pregnancy

          -  Vaginal bleeding, heavier than spotting, after 15 weeks 6 days

          -  Amniotic membranes prolapsed beyond external os

          -  Preterm rupture of membranes

          -  Fetal anomaly

          -  Pregnancy without a viable fetus

          -  Current or planned cervical cerclage

          -  Congenital Mullerian abnormality of the uterus

          -  Contraindication to intra-muscular injections

          -  Hypertension requiring medication

          -  Diabetes managed with insulin or oral hypoglycemic agents

          -  DES exposure

          -  Cervical surgery such as cold knife conization

          -  Planned indicated preterm delivery

          -  Participation in another interventional study that influences age at delivery

          -  Participation in this trial in a previous pregnancy

          -  Prenatal care or delivery planned outside a MFMU Network center
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William Grobman, MD, MBA</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Menachem Miodovnik, MD</last_name>
    <role>Study Director</role>
    <affiliation>NICHD Project Scientist</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama - Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35429</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University-Prentice Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept of OB/GYN, Hutzel Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University-St. Luke's Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina - Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Case Western Reserve-Metrohealth</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Sciences University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh-Magee Womens Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brown University -Women and Infants Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept of OB/GYN, Southwestern Medical Center, University of Texas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235-9032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Medical Branch - Galveston</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77555</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas-Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah Medical Center</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.bsc.gwu.edu/mfmu</url>
    <description>Click here for more information about the SCAN protocol</description>
  </link>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>February 21, 2007</study_first_submitted>
  <study_first_submitted_qc>February 21, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 23, 2007</study_first_posted>
  <results_first_submitted>February 28, 2019</results_first_submitted>
  <results_first_submitted_qc>March 19, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">April 11, 2019</results_first_posted>
  <last_update_submitted>July 11, 2019</last_update_submitted>
  <last_update_submitted_qc>July 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>nulliparous</keyword>
  <keyword>pregnancy</keyword>
  <keyword>short cervix</keyword>
  <keyword>progesterone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Premature Birth</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>17 alpha-Hydroxyprogesterone Caproate</mesh_term>
    <mesh_term>11-hydroxyprogesterone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The dataset will be shared per NIH policy after the completion and publication of the main analyses. Requests for datasets can be sent to mfmudatasets@bsc.gwu.edu</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>From April 2007 through May 2011, the fourteen centers of the Maternal-Fetal Medicine Units Network of the Eunice Kennedy Shriver National Institute of Child Health and Human Development participated in this randomized double-blind placebo-controlled trial. Eligible women were offered participation.</recruitment_details>
      <pre_assignment_details>Women who signed informed consent received a “compliance” injection of the placebo and were asked to return at least 3 days later for randomization. If a woman did not return for a randomization visit before 23 weeks 0 days of gestation, she was excluded.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>17 Alpha-hydroxyprogesterone Caproate</title>
          <description>17 alpha-hydroxyprogesterone caproate
17 alpha-hydroxyprogesterone caproate : Coded study medication is sterile solution containing 250 mg/mL of 17 alpha-hydroxyprogesterone caproate in castor oil with benzyl benzoate and benzyl alcohol as a preservative; placebo is same without the active ingredient. Study drug is administered as weekly 1 ml intramuscular injections until 36 week 6 days of gestation or delivery, whichever occurs first.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>castor oil</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="327"/>
                <participants group_id="P2" count="330"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="327"/>
                <participants group_id="P2" count="330"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>17 Alpha-hydroxyprogesterone Caproate</title>
          <description>17 alpha-hydroxyprogesterone caproate
17 alpha-hydroxyprogesterone caproate : Coded study medication is sterile solution containing 250 mg/mL of 17 alpha-hydroxyprogesterone caproate in castor oil with benzyl benzoate and benzyl alcohol as a preservative; placebo is same without the active ingredient. Study drug is administered as weekly 1 ml intramuscular injections until 36 week 6 days of gestation or delivery, whichever occurs first.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>castor oil</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="327"/>
            <count group_id="B2" value="330"/>
            <count group_id="B3" value="657"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="327"/>
                    <count group_id="B2" value="330"/>
                    <count group_id="B3" value="657"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22.8" spread="5.3"/>
                    <measurement group_id="B2" value="21.6" spread="4.4"/>
                    <measurement group_id="B3" value="22.2" spread="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="327"/>
                    <count group_id="B2" value="330"/>
                    <count group_id="B3" value="657"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="327"/>
                    <measurement group_id="B2" value="330"/>
                    <measurement group_id="B3" value="657"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Non-Hispanic white</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="327"/>
                    <count group_id="B2" value="330"/>
                    <count group_id="B3" value="657"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                    <measurement group_id="B2" value="74"/>
                    <measurement group_id="B3" value="150"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-hispanic black</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="327"/>
                    <count group_id="B2" value="330"/>
                    <count group_id="B3" value="657"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="179"/>
                    <measurement group_id="B2" value="161"/>
                    <measurement group_id="B3" value="340"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic white</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="327"/>
                    <count group_id="B2" value="330"/>
                    <count group_id="B3" value="657"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic black</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="327"/>
                    <count group_id="B2" value="330"/>
                    <count group_id="B3" value="657"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="327"/>
                    <count group_id="B2" value="330"/>
                    <count group_id="B3" value="657"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="327"/>
                    <count group_id="B2" value="330"/>
                    <count group_id="B3" value="657"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prepregnancy body mass index</title>
          <units>kg^m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="327"/>
                    <count group_id="B2" value="330"/>
                    <count group_id="B3" value="657"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.1" spread="6.9"/>
                    <measurement group_id="B2" value="25.4" spread="6.5"/>
                    <measurement group_id="B3" value="25.7" spread="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior Pregnancy</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>&lt;13 wk of gestation</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="327"/>
                    <count group_id="B2" value="330"/>
                    <count group_id="B3" value="657"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="92"/>
                    <measurement group_id="B2" value="82"/>
                    <measurement group_id="B3" value="174"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>13-19 wk of gestation</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="327"/>
                    <count group_id="B2" value="330"/>
                    <count group_id="B3" value="657"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Payment for obstetric care</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Uninsured/self-pay</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="327"/>
                    <count group_id="B2" value="330"/>
                    <count group_id="B3" value="657"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Private insurance</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="327"/>
                    <count group_id="B2" value="330"/>
                    <count group_id="B3" value="657"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="74"/>
                    <measurement group_id="B2" value="62"/>
                    <measurement group_id="B3" value="136"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Government-assisted insurance</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="327"/>
                    <count group_id="B2" value="330"/>
                    <count group_id="B3" value="657"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="236"/>
                    <measurement group_id="B2" value="238"/>
                    <measurement group_id="B3" value="474"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Married or living with partner</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="327"/>
                    <count group_id="B2" value="330"/>
                    <count group_id="B3" value="657"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="125"/>
                    <measurement group_id="B2" value="110"/>
                    <measurement group_id="B3" value="235"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Alcohol use during pregnancy</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="327"/>
                    <count group_id="B2" value="330"/>
                    <count group_id="B3" value="657"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoking during pregnancy</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="327"/>
                    <count group_id="B2" value="330"/>
                    <count group_id="B3" value="657"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="62"/>
                    <measurement group_id="B3" value="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Illicit substance use during pregnancy</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="327"/>
                    <count group_id="B2" value="330"/>
                    <count group_id="B3" value="657"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gestational age at randomization</title>
          <units>weeks</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="327"/>
                    <count group_id="B2" value="330"/>
                    <count group_id="B3" value="657"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21.4" spread="1.2"/>
                    <measurement group_id="B2" value="21.3" spread="1.3"/>
                    <measurement group_id="B3" value="21.4" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cervical length at screening</title>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="327"/>
                    <count group_id="B2" value="330"/>
                    <count group_id="B3" value="657"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23.9" spread="5.6"/>
                    <measurement group_id="B2" value="23.8" spread="5.7"/>
                    <measurement group_id="B3" value="23.8" spread="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cervical length at screening &lt;15mm</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="327"/>
                    <count group_id="B2" value="330"/>
                    <count group_id="B3" value="657"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cervical funnel present</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="327"/>
                    <count group_id="B2" value="330"/>
                    <count group_id="B3" value="657"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="88"/>
                    <measurement group_id="B2" value="69"/>
                    <measurement group_id="B3" value="157"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cervical funnel length</title>
          <population>Includes only the patients that had a cervical funnel present.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="88"/>
                    <count group_id="B2" value="69"/>
                    <count group_id="B3" value="157"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14.8" spread="8.0"/>
                    <measurement group_id="B2" value="16.7" spread="8.7"/>
                    <measurement group_id="B3" value="15.6" spread="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Debris present</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="327"/>
                    <count group_id="B2" value="330"/>
                    <count group_id="B3" value="657"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Delivering Before 37 Weeks Gestation</title>
        <description>Number of participants delivering before 37 weeks gestation by indication</description>
        <time_frame>Delivery before 37 weeks gestation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>17 Alpha-hydroxyprogesterone Caproate</title>
            <description>17 alpha-hydroxyprogesterone caproate
17 alpha-hydroxyprogesterone caproate : Coded study medication is sterile solution containing 250 mg/mL of 17 alpha-hydroxyprogesterone caproate in castor oil with benzyl benzoate and benzyl alcohol as a preservative; placebo is same without the active ingredient. Study drug is administered as weekly 1 ml intramuscular injections until 36 week 6 days of gestation or delivery, whichever occurs first.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>castor oil</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Delivering Before 37 Weeks Gestation</title>
          <description>Number of participants delivering before 37 weeks gestation by indication</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="327"/>
                <count group_id="O2" value="330"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total Delivery &lt;37 wk</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82"/>
                    <measurement group_id="O2" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spontaneous</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medically indicated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fetal loss/abortion &lt;20 wk</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>All deliveries less than 37 weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.79</ci_lower_limit>
            <ci_upper_limit>1.35</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Spontaneous deliveries</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.70</ci_lower_limit>
            <ci_upper_limit>1.40</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Medically-indicated deliveries</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.09</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.65</ci_lower_limit>
            <ci_upper_limit>1.84</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Gestational Age at Delivery</title>
        <description>Mean gestational age at delivery</description>
        <time_frame>Delivery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>17 Alpha-hydroxyprogesterone Caproate</title>
            <description>17 alpha-hydroxyprogesterone caproate
17 alpha-hydroxyprogesterone caproate : Coded study medication is sterile solution containing 250 mg/mL of 17 alpha-hydroxyprogesterone caproate in castor oil with benzyl benzoate and benzyl alcohol as a preservative; placebo is same without the active ingredient. Study drug is administered as weekly 1 ml intramuscular injections until 36 week 6 days of gestation or delivery, whichever occurs first.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>castor oil</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Gestational Age at Delivery</title>
          <description>Mean gestational age at delivery</description>
          <units>weeks</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="327"/>
                <count group_id="O2" value="330"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.6" spread="3.9"/>
                    <measurement group_id="O2" value="37.4" spread="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.93</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Preterm Premature Rupture of Membranes</title>
        <time_frame>&lt;37 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>17 Alpha-hydroxyprogesterone Caproate</title>
            <description>17 alpha-hydroxyprogesterone caproate
17 alpha-hydroxyprogesterone caproate : Coded study medication is sterile solution containing 250 mg/mL of 17 alpha-hydroxyprogesterone caproate in castor oil with benzyl benzoate and benzyl alcohol as a preservative; placebo is same without the active ingredient. Study drug is administered as weekly 1 ml intramuscular injections until 36 week 6 days of gestation or delivery, whichever occurs first.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>castor oil</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Preterm Premature Rupture of Membranes</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="327"/>
                <count group_id="O2" value="330"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.61</ci_lower_limit>
            <ci_upper_limit>1.80</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Delivered Before 35 Weeks Gestation</title>
        <description>Delivery before 35 weeks gestation</description>
        <time_frame>Delivery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>17 Alpha-hydroxyprogesterone Caproate</title>
            <description>17 alpha-hydroxyprogesterone caproate
17 alpha-hydroxyprogesterone caproate : Coded study medication is sterile solution containing 250 mg/mL of 17 alpha-hydroxyprogesterone caproate in castor oil with benzyl benzoate and benzyl alcohol as a preservative; placebo is same without the active ingredient. Study drug is administered as weekly 1 ml intramuscular injections until 36 week 6 days of gestation or delivery, whichever occurs first.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>castor oil</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Delivered Before 35 Weeks Gestation</title>
          <description>Delivery before 35 weeks gestation</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="327"/>
                <count group_id="O2" value="330"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.84</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.58</ci_lower_limit>
            <ci_upper_limit>1.21</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Delivered Before 32 Weeks Gestation</title>
        <description>Delivery before 32 weeks gestation</description>
        <time_frame>Delivery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>17 Alpha-hydroxyprogesterone Caproate</title>
            <description>17 alpha-hydroxyprogesterone caproate
17 alpha-hydroxyprogesterone caproate : Coded study medication is sterile solution containing 250 mg/mL of 17 alpha-hydroxyprogesterone caproate in castor oil with benzyl benzoate and benzyl alcohol as a preservative; placebo is same without the active ingredient. Study drug is administered as weekly 1 ml intramuscular injections until 36 week 6 days of gestation or delivery, whichever occurs first.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>castor oil</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Delivered Before 32 Weeks Gestation</title>
          <description>Delivery before 32 weeks gestation</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="327"/>
                <count group_id="O2" value="330"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.88</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.54</ci_lower_limit>
            <ci_upper_limit>1.43</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Delivered Before 28 Weeks Gestation</title>
        <description>Delivery before 28 weeks gestation</description>
        <time_frame>Delivery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>17 Alpha-hydroxyprogesterone Caproate</title>
            <description>17 alpha-hydroxyprogesterone caproate
17 alpha-hydroxyprogesterone caproate : Coded study medication is sterile solution containing 250 mg/mL of 17 alpha-hydroxyprogesterone caproate in castor oil with benzyl benzoate and benzyl alcohol as a preservative; placebo is same without the active ingredient. Study drug is administered as weekly 1 ml intramuscular injections until 36 week 6 days of gestation or delivery, whichever occurs first.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>castor oil</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Delivered Before 28 Weeks Gestation</title>
          <description>Delivery before 28 weeks gestation</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="327"/>
                <count group_id="O2" value="330"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.69</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.36</ci_lower_limit>
            <ci_upper_limit>1.30</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Visited the Hospital Due to Preterm Labor</title>
        <description>Number of participants who visited the hospital due to preterm labor before 37 weeks gestation</description>
        <time_frame>Between randomization and 37 weeks gestation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>17 Alpha-hydroxyprogesterone Caproate</title>
            <description>17 alpha-hydroxyprogesterone caproate
17 alpha-hydroxyprogesterone caproate : Coded study medication is sterile solution containing 250 mg/mL of 17 alpha-hydroxyprogesterone caproate in castor oil with benzyl benzoate and benzyl alcohol as a preservative; placebo is same without the active ingredient. Study drug is administered as weekly 1 ml intramuscular injections until 36 week 6 days of gestation or delivery, whichever occurs first.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>castor oil</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Visited the Hospital Due to Preterm Labor</title>
          <description>Number of participants who visited the hospital due to preterm labor before 37 weeks gestation</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="327"/>
                <count group_id="O2" value="330"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="145"/>
                    <measurement group_id="O2" value="151"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.97</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.82</ci_lower_limit>
            <ci_upper_limit>1.15</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Underwent Tocolytic Therapy</title>
        <description>Number of participants who underwent tocolytic therapy during pregnancy</description>
        <time_frame>Any time during pregnancy from randomization to delivery, a timeframe up to 20 weeks</time_frame>
        <population>Data was missing for 6 participants in the treatment group and 5 participants in the placebo group.</population>
        <group_list>
          <group group_id="O1">
            <title>17 Alpha-hydroxyprogesterone Caproate</title>
            <description>17 alpha-hydroxyprogesterone caproate
17 alpha-hydroxyprogesterone caproate : Coded study medication is sterile solution containing 250 mg/mL of 17 alpha-hydroxyprogesterone caproate in castor oil with benzyl benzoate and benzyl alcohol as a preservative; placebo is same without the active ingredient. Study drug is administered as weekly 1 ml intramuscular injections until 36 week 6 days of gestation or delivery, whichever occurs first.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>castor oil</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Underwent Tocolytic Therapy</title>
          <description>Number of participants who underwent tocolytic therapy during pregnancy</description>
          <population>Data was missing for 6 participants in the treatment group and 5 participants in the placebo group.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="321"/>
                <count group_id="O2" value="325"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.84</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.55</ci_lower_limit>
            <ci_upper_limit>1.29</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Underwent Corticosteroid Therapy</title>
        <description>Number of participants who underwent corticosteroid therapy in pregnancy</description>
        <time_frame>Any time during pregnancy from randomization to delivery, a timeframe up to 20 weeks</time_frame>
        <population>Data was missing for 6 participants in the treatment group and 5 participants in the placebo group.</population>
        <group_list>
          <group group_id="O1">
            <title>17 Alpha-hydroxyprogesterone Caproate</title>
            <description>17 alpha-hydroxyprogesterone caproate
17 alpha-hydroxyprogesterone caproate : Coded study medication is sterile solution containing 250 mg/mL of 17 alpha-hydroxyprogesterone caproate in castor oil with benzyl benzoate and benzyl alcohol as a preservative; placebo is same without the active ingredient. Study drug is administered as weekly 1 ml intramuscular injections until 36 week 6 days of gestation or delivery, whichever occurs first.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>castor oil</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Underwent Corticosteroid Therapy</title>
          <description>Number of participants who underwent corticosteroid therapy in pregnancy</description>
          <population>Data was missing for 6 participants in the treatment group and 5 participants in the placebo group.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="321"/>
                <count group_id="O2" value="325"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.09</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.77</ci_lower_limit>
            <ci_upper_limit>1.55</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Had a Cerclage Placement</title>
        <description>Number of participants who had a cerclage placement</description>
        <time_frame>Any time during pregnancy from randomization to delivery, a timeframe up to 20 weeks</time_frame>
        <population>Data was missing for 6 participants in the treatment group and 5 participants in the placebo group.</population>
        <group_list>
          <group group_id="O1">
            <title>17 Alpha-hydroxyprogesterone Caproate</title>
            <description>17 alpha-hydroxyprogesterone caproate
17 alpha-hydroxyprogesterone caproate : Coded study medication is sterile solution containing 250 mg/mL of 17 alpha-hydroxyprogesterone caproate in castor oil with benzyl benzoate and benzyl alcohol as a preservative; placebo is same without the active ingredient. Study drug is administered as weekly 1 ml intramuscular injections until 36 week 6 days of gestation or delivery, whichever occurs first.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>castor oil</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Had a Cerclage Placement</title>
          <description>Number of participants who had a cerclage placement</description>
          <population>Data was missing for 6 participants in the treatment group and 5 participants in the placebo group.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="321"/>
                <count group_id="O2" value="325"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.52</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.43</ci_lower_limit>
            <ci_upper_limit>5.33</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experiencing Gestational Hypertension or Preeclampsia</title>
        <time_frame>Any time during pregnancy from randomization to delivery, a timeframe up to 20 weeks</time_frame>
        <population>Data was missing for 1 participant in the placebo group.</population>
        <group_list>
          <group group_id="O1">
            <title>17 Alpha-hydroxyprogesterone Caproate</title>
            <description>17 alpha-hydroxyprogesterone caproate
17 alpha-hydroxyprogesterone caproate : Coded study medication is sterile solution containing 250 mg/mL of 17 alpha-hydroxyprogesterone caproate in castor oil with benzyl benzoate and benzyl alcohol as a preservative; placebo is same without the active ingredient. Study drug is administered as weekly 1 ml intramuscular injections until 36 week 6 days of gestation or delivery, whichever occurs first.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>castor oil</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing Gestational Hypertension or Preeclampsia</title>
          <population>Data was missing for 1 participant in the placebo group.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="327"/>
                <count group_id="O2" value="329"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.16</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.78</ci_lower_limit>
            <ci_upper_limit>1.72</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Gestational Diabetes Mellitus</title>
        <time_frame>Any time during pregnancy from randomization to delivery, a timeframe up to 20 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>17 Alpha-hydroxyprogesterone Caproate</title>
            <description>17 alpha-hydroxyprogesterone caproate
17 alpha-hydroxyprogesterone caproate : Coded study medication is sterile solution containing 250 mg/mL of 17 alpha-hydroxyprogesterone caproate in castor oil with benzyl benzoate and benzyl alcohol as a preservative; placebo is same without the active ingredient. Study drug is administered as weekly 1 ml intramuscular injections until 36 week 6 days of gestation or delivery, whichever occurs first.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>castor oil</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Gestational Diabetes Mellitus</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="327"/>
                <count group_id="O2" value="330"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.16</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.56</ci_lower_limit>
            <ci_upper_limit>2.41</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experiencing Cholestasis</title>
        <time_frame>Any time during pregnancy from randomization to delivery, a timeframe up to 20 weeks</time_frame>
        <population>Data was missing for 1 participant in the Placebo group</population>
        <group_list>
          <group group_id="O1">
            <title>17 Alpha-hydroxyprogesterone Caproate</title>
            <description>17 alpha-hydroxyprogesterone caproate
17 alpha-hydroxyprogesterone caproate : Coded study medication is sterile solution containing 250 mg/mL of 17 alpha-hydroxyprogesterone caproate in castor oil with benzyl benzoate and benzyl alcohol as a preservative; placebo is same without the active ingredient. Study drug is administered as weekly 1 ml intramuscular injections until 36 week 6 days of gestation or delivery, whichever occurs first.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>castor oil</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing Cholestasis</title>
          <population>Data was missing for 1 participant in the Placebo group</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="327"/>
                <count group_id="O2" value="329"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Experienced Placental Abruption</title>
        <time_frame>Any time during pregnancy from randomization to delivery, a timeframe up to 20 weeks</time_frame>
        <population>Data was missing for 2 participants in the placebo group.</population>
        <group_list>
          <group group_id="O1">
            <title>17 Alpha-hydroxyprogesterone Caproate</title>
            <description>17 alpha-hydroxyprogesterone caproate
17 alpha-hydroxyprogesterone caproate : Coded study medication is sterile solution containing 250 mg/mL of 17 alpha-hydroxyprogesterone caproate in castor oil with benzyl benzoate and benzyl alcohol as a preservative; placebo is same without the active ingredient. Study drug is administered as weekly 1 ml intramuscular injections until 36 week 6 days of gestation or delivery, whichever occurs first.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>castor oil</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Experienced Placental Abruption</title>
          <population>Data was missing for 2 participants in the placebo group.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="327"/>
                <count group_id="O2" value="328"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.74</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.34</ci_lower_limit>
            <ci_upper_limit>1.58</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Experienced Chorioamnionitis</title>
        <time_frame>Any time during pregnancy from randomization to delivery, a timeframe up to 20 weeks</time_frame>
        <population>Data was missing for 2 participants in the placebo group.</population>
        <group_list>
          <group group_id="O1">
            <title>17 Alpha-hydroxyprogesterone Caproate</title>
            <description>17 alpha-hydroxyprogesterone caproate
17 alpha-hydroxyprogesterone caproate : Coded study medication is sterile solution containing 250 mg/mL of 17 alpha-hydroxyprogesterone caproate in castor oil with benzyl benzoate and benzyl alcohol as a preservative; placebo is same without the active ingredient. Study drug is administered as weekly 1 ml intramuscular injections until 36 week 6 days of gestation or delivery, whichever occurs first.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>castor oil</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Experienced Chorioamnionitis</title>
          <population>Data was missing for 2 participants in the placebo group.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="327"/>
                <count group_id="O2" value="328"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.45</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.84</ci_lower_limit>
            <ci_upper_limit>2.52</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Had Cesarean Delivery</title>
        <time_frame>delivery</time_frame>
        <population>Data was missing for 1 participant in the placebo group.</population>
        <group_list>
          <group group_id="O1">
            <title>17 Alpha-hydroxyprogesterone Caproate</title>
            <description>17 alpha-hydroxyprogesterone caproate
17 alpha-hydroxyprogesterone caproate : Coded study medication is sterile solution containing 250 mg/mL of 17 alpha-hydroxyprogesterone caproate in castor oil with benzyl benzoate and benzyl alcohol as a preservative; placebo is same without the active ingredient. Study drug is administered as weekly 1 ml intramuscular injections until 36 week 6 days of gestation or delivery, whichever occurs first.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>castor oil</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Had Cesarean Delivery</title>
          <population>Data was missing for 1 participant in the placebo group.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="327"/>
                <count group_id="O2" value="329"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67"/>
                    <measurement group_id="O2" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.79</ci_lower_limit>
            <ci_upper_limit>1.46</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Reported Side Effects</title>
        <description>Number of participants who reported any side effect, nausea, urticaria, and/or an issue at the injection site</description>
        <time_frame>Any time during pregnancy from randomization to delivery, a timeframe up to 20 weeks</time_frame>
        <population>Data was missing for 1 participant in the treatment group and 2 participants in the placebo group.</population>
        <group_list>
          <group group_id="O1">
            <title>17 Alpha-hydroxyprogesterone Caproate</title>
            <description>17 alpha-hydroxyprogesterone caproate
17 alpha-hydroxyprogesterone caproate : Coded study medication is sterile solution containing 250 mg/mL of 17 alpha-hydroxyprogesterone caproate in castor oil with benzyl benzoate and benzyl alcohol as a preservative; placebo is same without the active ingredient. Study drug is administered as weekly 1 ml intramuscular injections until 36 week 6 days of gestation or delivery, whichever occurs first.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>castor oil</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Reported Side Effects</title>
          <description>Number of participants who reported any side effect, nausea, urticaria, and/or an issue at the injection site</description>
          <population>Data was missing for 1 participant in the treatment group and 2 participants in the placebo group.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="326"/>
                <count group_id="O2" value="328"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="223"/>
                    <measurement group_id="O2" value="220"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="217"/>
                    <measurement group_id="O2" value="209"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urticaria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Any side effect</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.92</ci_lower_limit>
            <ci_upper_limit>1.13</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Injection site</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.93</ci_lower_limit>
            <ci_upper_limit>1.17</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Urticaria</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>5.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.11</ci_lower_limit>
            <ci_upper_limit>22.78</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Nausea</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.70</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.27</ci_lower_limit>
            <ci_upper_limit>1.83</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Meeting the Composite Adverse Perinatal Outcome and Components</title>
        <description>comprised of fetal or infant death, respiratory distress syndrome, intraventricular hemorrhage (grades 3 and 4), periventricular leukomalacia, necrotizing enterocolitis (stage II and III), Bronchopulmonary dysplasia /chronic lung disease, retinopathy of prematurity (stage III or higher), early onset sepsis</description>
        <time_frame>within 72 hours of delivery</time_frame>
        <population>With the exception of the composite outcome and death, the neonatal outcomes were only measured for live births.</population>
        <group_list>
          <group group_id="O1">
            <title>17 Alpha-hydroxyprogesterone Caproate</title>
            <description>17 alpha-hydroxyprogesterone caproate
17 alpha-hydroxyprogesterone caproate : Coded study medication is sterile solution containing 250 mg/mL of 17 alpha-hydroxyprogesterone caproate in castor oil with benzyl benzoate and benzyl alcohol as a preservative; placebo is same without the active ingredient. Study drug is administered as weekly 1 ml intramuscular injections until 36 week 6 days of gestation or delivery, whichever occurs first.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>castor oil</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Meeting the Composite Adverse Perinatal Outcome and Components</title>
          <description>comprised of fetal or infant death, respiratory distress syndrome, intraventricular hemorrhage (grades 3 and 4), periventricular leukomalacia, necrotizing enterocolitis (stage II and III), Bronchopulmonary dysplasia /chronic lung disease, retinopathy of prematurity (stage III or higher), early onset sepsis</description>
          <population>With the exception of the composite outcome and death, the neonatal outcomes were only measured for live births.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="327"/>
                <count group_id="O2" value="330"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Composite Outcome Total</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="327"/>
                    <count group_id="O2" value="330"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fetal Death</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="327"/>
                    <count group_id="O2" value="330"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neonatal Death</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="327"/>
                    <count group_id="O2" value="330"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Respiratory Distress Syndrome</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="320"/>
                    <count group_id="O2" value="323"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bronchopulmonary dysplasia</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="320"/>
                    <count group_id="O2" value="322"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Necrotizing enterocolitis, grade II or III</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="320"/>
                    <count group_id="O2" value="322"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intraventricular Hemorrhage, Grade III or IV</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="320"/>
                    <count group_id="O2" value="322"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Periventricular Leukomalacia</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="327"/>
                    <count group_id="O2" value="330"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Early-onset Sepsis</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="320"/>
                    <count group_id="O2" value="322"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Retinopathy of prematurity, grade II or IV</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="320"/>
                    <count group_id="O2" value="322"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis is for the total composite</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.77</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.46</ci_lower_limit>
            <ci_upper_limit>1.30</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Birth Weight</title>
        <description>Birth weight as measured in grams</description>
        <time_frame>Delivery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>17 Alpha-hydroxyprogesterone Caproate</title>
            <description>17 alpha-hydroxyprogesterone caproate
17 alpha-hydroxyprogesterone caproate : Coded study medication is sterile solution containing 250 mg/mL of 17 alpha-hydroxyprogesterone caproate in castor oil with benzyl benzoate and benzyl alcohol as a preservative; placebo is same without the active ingredient. Study drug is administered as weekly 1 ml intramuscular injections until 36 week 6 days of gestation or delivery, whichever occurs first.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>castor oil</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Birth Weight</title>
          <description>Birth weight as measured in grams</description>
          <units>Grams</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="327"/>
                <count group_id="O2" value="330"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2855" spread="747"/>
                    <measurement group_id="O2" value="2824" spread="807"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.82</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Birth Weight by Count of Participants</title>
        <description>Birth weight by count of participants &lt; 2500 grams and &lt; 1500 grams</description>
        <time_frame>Delivery</time_frame>
        <population>Data was missing for 4 participants in the treatment group and 2 participants in the placebo group.</population>
        <group_list>
          <group group_id="O1">
            <title>17 Alpha-hydroxyprogesterone Caproate</title>
            <description>17 alpha-hydroxyprogesterone caproate
17 alpha-hydroxyprogesterone caproate : Coded study medication is sterile solution containing 250 mg/mL of 17 alpha-hydroxyprogesterone caproate in castor oil with benzyl benzoate and benzyl alcohol as a preservative; placebo is same without the active ingredient. Study drug is administered as weekly 1 ml intramuscular injections until 36 week 6 days of gestation or delivery, whichever occurs first.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>castor oil</description>
          </group>
        </group_list>
        <measure>
          <title>Birth Weight by Count of Participants</title>
          <description>Birth weight by count of participants &lt; 2500 grams and &lt; 1500 grams</description>
          <population>Data was missing for 4 participants in the treatment group and 2 participants in the placebo group.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="323"/>
                <count group_id="O2" value="328"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Birth weight &lt; 2500g</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72"/>
                    <measurement group_id="O2" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Birth weight &lt; 1500g</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Neonates Who Measured Small for Gestational Age</title>
        <description>Birth weight percentile and small for gestational age &lt;10th percentile based on number of weeks and gender.</description>
        <time_frame>Delivery</time_frame>
        <population>Data was missing for 4 participants in the treatment group and 2 participants in the placebo group.</population>
        <group_list>
          <group group_id="O1">
            <title>17 Alpha-hydroxyprogesterone Caproate</title>
            <description>17 alpha-hydroxyprogesterone caproate
17 alpha-hydroxyprogesterone caproate : Coded study medication is sterile solution containing 250 mg/mL of 17 alpha-hydroxyprogesterone caproate in castor oil with benzyl benzoate and benzyl alcohol as a preservative; placebo is same without the active ingredient. Study drug is administered as weekly 1 ml intramuscular injections until 36 week 6 days of gestation or delivery, whichever occurs first.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>castor oil</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Neonates Who Measured Small for Gestational Age</title>
          <description>Birth weight percentile and small for gestational age &lt;10th percentile based on number of weeks and gender.</description>
          <population>Data was missing for 4 participants in the treatment group and 2 participants in the placebo group.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="323"/>
                <count group_id="O2" value="328"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&lt; 10th percentile</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt; 3rd percentile</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Apgar Score of Less Than 7 at 5 Minutes</title>
        <description>The Apgar score is a simple method of quickly assessing the health and vital signs of a newborn baby created by and named after Dr. Virginia Apgar. Apgar testing assesses Appearance, Pulse, Grimace and Activity in a newborn and is typically done at one and five minutes after a baby is born, and it may be repeated at 10, 15, and 20 minutes if the score is low. The five criteria are each scored as 0, 1, or 2 (two being the best), and the total score is calculated by then adding the five values obtained. Agar scores of 0-3 are critically low, 4-6 are below normal, and indicate that the baby likely requires medical intervention, scores of 7+ are considered normal. The lower the Apgar score, the more alert the medical team should be to the possibility of the baby requiring intervention. Some components of the Apgar score are subjective, and there are cases in which a baby requires urgent medical treatment despite having a high Apgar score.</description>
        <time_frame>5 minutes post delivery</time_frame>
        <population>Data was missing for 4 participants in the treatment group and 2 participants in the placebo group.</population>
        <group_list>
          <group group_id="O1">
            <title>17 Alpha-hydroxyprogesterone Caproate</title>
            <description>17 alpha-hydroxyprogesterone caproate
17 alpha-hydroxyprogesterone caproate : Coded study medication is sterile solution containing 250 mg/mL of 17 alpha-hydroxyprogesterone caproate in castor oil with benzyl benzoate and benzyl alcohol as a preservative; placebo is same without the active ingredient. Study drug is administered as weekly 1 ml intramuscular injections until 36 week 6 days of gestation or delivery, whichever occurs first.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>castor oil</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Apgar Score of Less Than 7 at 5 Minutes</title>
          <description>The Apgar score is a simple method of quickly assessing the health and vital signs of a newborn baby created by and named after Dr. Virginia Apgar. Apgar testing assesses Appearance, Pulse, Grimace and Activity in a newborn and is typically done at one and five minutes after a baby is born, and it may be repeated at 10, 15, and 20 minutes if the score is low. The five criteria are each scored as 0, 1, or 2 (two being the best), and the total score is calculated by then adding the five values obtained. Agar scores of 0-3 are critically low, 4-6 are below normal, and indicate that the baby likely requires medical intervention, scores of 7+ are considered normal. The lower the Apgar score, the more alert the medical team should be to the possibility of the baby requiring intervention. Some components of the Apgar score are subjective, and there are cases in which a baby requires urgent medical treatment despite having a high Apgar score.</description>
          <population>Data was missing for 4 participants in the treatment group and 2 participants in the placebo group.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="323"/>
                <count group_id="O2" value="328"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Neonates With a Major Congenital Anomaly</title>
        <description>Presence of a major congenital anomaly at birth</description>
        <time_frame>Delivery</time_frame>
        <population>Data was missing for 1 participant in the treatment group and 2 participants in the placebo group.</population>
        <group_list>
          <group group_id="O1">
            <title>17 Alpha-hydroxyprogesterone Caproate</title>
            <description>17 alpha-hydroxyprogesterone caproate
17 alpha-hydroxyprogesterone caproate : Coded study medication is sterile solution containing 250 mg/mL of 17 alpha-hydroxyprogesterone caproate in castor oil with benzyl benzoate and benzyl alcohol as a preservative; placebo is same without the active ingredient. Study drug is administered as weekly 1 ml intramuscular injections until 36 week 6 days of gestation or delivery, whichever occurs first.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>castor oil</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Neonates With a Major Congenital Anomaly</title>
          <description>Presence of a major congenital anomaly at birth</description>
          <population>Data was missing for 1 participant in the treatment group and 2 participants in the placebo group.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="326"/>
                <count group_id="O2" value="328"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Neonates With Patent Ductus Arteriosus</title>
        <description>Number of neonates diagnosed with the heart defect patent ductus arteriosus</description>
        <time_frame>Delivery through neonatal discharge</time_frame>
        <population>Data was missing for 7 participants in the treatment group and 8 participants in the placebo group.</population>
        <group_list>
          <group group_id="O1">
            <title>17 Alpha-hydroxyprogesterone Caproate</title>
            <description>17 alpha-hydroxyprogesterone caproate
17 alpha-hydroxyprogesterone caproate : Coded study medication is sterile solution containing 250 mg/mL of 17 alpha-hydroxyprogesterone caproate in castor oil with benzyl benzoate and benzyl alcohol as a preservative; placebo is same without the active ingredient. Study drug is administered as weekly 1 ml intramuscular injections until 36 week 6 days of gestation or delivery, whichever occurs first.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>castor oil</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Neonates With Patent Ductus Arteriosus</title>
          <description>Number of neonates diagnosed with the heart defect patent ductus arteriosus</description>
          <population>Data was missing for 7 participants in the treatment group and 8 participants in the placebo group.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="320"/>
                <count group_id="O2" value="322"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Neonates Experiencing Seizures</title>
        <description>Number of neonates experiencing seizures from delivery to hospital discharge</description>
        <time_frame>Delivery through neonatal discharge</time_frame>
        <population>Data was missing for 7 participants in the treatment group and 8 participants in the placebo group.</population>
        <group_list>
          <group group_id="O1">
            <title>17 Alpha-hydroxyprogesterone Caproate</title>
            <description>17 alpha-hydroxyprogesterone caproate
17 alpha-hydroxyprogesterone caproate : Coded study medication is sterile solution containing 250 mg/mL of 17 alpha-hydroxyprogesterone caproate in castor oil with benzyl benzoate and benzyl alcohol as a preservative; placebo is same without the active ingredient. Study drug is administered as weekly 1 ml intramuscular injections until 36 week 6 days of gestation or delivery, whichever occurs first.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>castor oil</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Neonates Experiencing Seizures</title>
          <description>Number of neonates experiencing seizures from delivery to hospital discharge</description>
          <population>Data was missing for 7 participants in the treatment group and 8 participants in the placebo group.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="320"/>
                <count group_id="O2" value="322"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Neonates Admitted to NICU</title>
        <description>Admission to the neonatal intensive care unit</description>
        <time_frame>Delivery through hospital discharge</time_frame>
        <population>Data was missing for 5 participants in the treatment group and 1 participant in the placebo group.</population>
        <group_list>
          <group group_id="O1">
            <title>17 Alpha-hydroxyprogesterone Caproate</title>
            <description>17 alpha-hydroxyprogesterone caproate
17 alpha-hydroxyprogesterone caproate : Coded study medication is sterile solution containing 250 mg/mL of 17 alpha-hydroxyprogesterone caproate in castor oil with benzyl benzoate and benzyl alcohol as a preservative; placebo is same without the active ingredient. Study drug is administered as weekly 1 ml intramuscular injections until 36 week 6 days of gestation or delivery, whichever occurs first.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>castor oil</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Neonates Admitted to NICU</title>
          <description>Admission to the neonatal intensive care unit</description>
          <population>Data was missing for 5 participants in the treatment group and 1 participant in the placebo group.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="322"/>
                <count group_id="O2" value="329"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63"/>
                    <measurement group_id="O2" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Length of NICU Stay</title>
        <description>Median length of stay in the neonatal intensive care unit in days</description>
        <time_frame>NICU admission through NICU discharge</time_frame>
        <population>Data was missing for 5 participants in the treatment group and 1 participant in the placebo group.</population>
        <group_list>
          <group group_id="O1">
            <title>17 Alpha-hydroxyprogesterone Caproate</title>
            <description>17 alpha-hydroxyprogesterone caproate
17 alpha-hydroxyprogesterone caproate : Coded study medication is sterile solution containing 250 mg/mL of 17 alpha-hydroxyprogesterone caproate in castor oil with benzyl benzoate and benzyl alcohol as a preservative; placebo is same without the active ingredient. Study drug is administered as weekly 1 ml intramuscular injections until 36 week 6 days of gestation or delivery, whichever occurs first.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>castor oil</description>
          </group>
        </group_list>
        <measure>
          <title>Median Length of NICU Stay</title>
          <description>Median length of stay in the neonatal intensive care unit in days</description>
          <population>Data was missing for 5 participants in the treatment group and 1 participant in the placebo group.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="322"/>
                <count group_id="O2" value="329"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17" lower_limit="6" upper_limit="43"/>
                    <measurement group_id="O2" value="15.5" lower_limit="6" upper_limit="57.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.61</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data was collected during the study period of April 2007 through June 2010, from the time of the participants randomization through hospital discharge of the mother and baby (up to 60 days).</time_frame>
      <desc>Other adverse events that are related to side effects are available for patients who had at least 1 study visit. 1 randomized participant in the treatment group and 2 randomized participants in the placebo group did not attend a study visit after randomization. Therefore the Ns for other side effects are different than those for the serious adverse events and the study sample (by 3 participants total).</desc>
      <group_list>
        <group group_id="E1">
          <title>17 Alpha-hydroxyprogesterone Caproate</title>
          <description>250 mg of 17 alpha-hydroxyprogesterone caproate given by weekly injection until 37 weeks gestation or delivery
17 alpha-hydroxyprogesterone caproate: Coded study medication is sterile solution containing 250 mg/mL of 17 alpha-hydroxyprogesterone caproate in castor oil with benzyl benzoate and benzyl alcohol as a preservative; placebo is same without the active ingredient. Study drug is administered as weekly 1 ml intramuscular injections until 36 week 6 days of gestation or delivery, whichever occurs first.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo oil given by weekly injection until 37 weeks gestation or delivery.
Placebo Oil: Placebo oil is a 250 mg/mL solution of castor oil with benzyl benzoate and benzyl alcohol as a preservative</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="330"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Maternal blood disorders</sub_title>
                <description>Pulmonary embolism, thrombocytopenia</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Neonatal Hematochromatosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="330"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Maternal Pulmonary edema</sub_title>
                <description>due to anemia and cardiac insufficiency</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="330"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Congenital Anomalies</sub_title>
                <description>ovarian cyst, esophageal atresia, flexion contracture, hypospadias, patent ductus arteriosis, polydactyly, torticollis, Trisomy 21</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="330"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Neonatal death</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="330"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Miscarriage or stillbirth</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Miscarriage, antepartum stillbirth, intrapartum stillbirth</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Placental abruption</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Pregnancy Complications</sub_title>
                <description>advanced cervical dilation, oligohydramnios, preterm rupture of the membranes</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="330"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="330"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <description>Nosebleed</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="327"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="330"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="326" subjects_at_risk="326"/>
                <counts group_id="E2" subjects_affected="328" subjects_at_risk="328"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="326"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="328"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="326"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="328"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="326"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="328"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="326"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="328"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="326"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="328"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Reaction at injection site</sub_title>
                <counts group_id="E1" subjects_affected="217" subjects_at_risk="326"/>
                <counts group_id="E2" subjects_affected="210" subjects_at_risk="328"/>
              </event>
              <event>
                <sub_title>Sore/burn at injection site</sub_title>
                <counts group_id="E1" subjects_affected="145" subjects_at_risk="326"/>
                <counts group_id="E2" subjects_affected="153" subjects_at_risk="328"/>
              </event>
              <event>
                <sub_title>Itching at injection site</sub_title>
                <counts group_id="E1" subjects_affected="121" subjects_at_risk="326"/>
                <counts group_id="E2" subjects_affected="109" subjects_at_risk="328"/>
              </event>
              <event>
                <sub_title>Swelling/lump at injection site</sub_title>
                <counts group_id="E1" subjects_affected="107" subjects_at_risk="326"/>
                <counts group_id="E2" subjects_affected="93" subjects_at_risk="328"/>
              </event>
              <event>
                <sub_title>Bruising at injection site</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="326"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="328"/>
              </event>
              <event>
                <sub_title>Redness at injection site</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="326"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="328"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="326"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="328"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>William Grobman, MD</name_or_title>
      <organization>Northwestern University Medical School</organization>
      <phone>312-472-4661</phone>
      <email>w-grobman@northwestern.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

